Jonathan S. Hausmann

Jonathan S. Hausmann

Auto-generated profile, based on publicly available information

Jonathan S. Hausmann

Rheumatology, Boston Children's Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
ASAnja Strangfeld
Anja Strangfeld
MSMartin Schäfer
Martin Schäfer
MGMilena A Gianfrancesco
Milena A Gianfrancesco
SLSaskia Lawson-Tovey
Saskia Lawson-Tovey
JLJean W Liew
Jean W Liew
PMPedro M Machado
Pedro M Machado
Objectives To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category. Results Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66–75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death. Conclusion Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.

2 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
PLPui Y. Lee
Pui Y. Lee
MDMegan Day-Lewis
Megan Day-Lewis
LHLauren A. Henderson
Lauren A. Henderson
KFKevin G. Friedman
Kevin G. Friedman
JLJeffrey Lo
Jeffrey Lo
MSMary Beth F. Son
Mary Beth F. Son
BACKGROUND. Pediatric SARS–CoV-2 infection can be complicated by a dangerous hyperinflammatory condition termed multisystem inflammatory syndrome in children (MIS-C). The clinical and immunologic spectrum of MIS-C and its relationship to other inflammatory conditions of childhood have not been studied in detail. METHODS. We retrospectively studied confirmed cases of MIS-C at our institution from March to June 2020. The clinical characteristics, laboratory studies, and treatment response were collected. Data were compared with historic cohorts of Kawasaki disease (KD) and macrophage activation syndrome (MAS). RESULTS. Twenty-eight patients fulfilled the case definition of MIS-C. Median age at presentation was 9 years (range: 1 month to 17 years); 50% of patients had preexisting conditions. All patients had laboratory confirmation of SARS–CoV-2 infection. Seventeen patients (61%) required intensive care, including 7 patients (25%) who required inotrope support. Seven patients (25%) met criteria for complete or incomplete KD, and coronary abnormalities were found in 6 cases. Lymphopenia, thrombocytopenia, and elevation in inflammatory markers, D-dimer, B-type natriuretic peptide, IL-6, and IL-10 levels were common but not ubiquitous. Cytopenias distinguished MIS-C from KD and the degree of hyperferritinemia and pattern of cytokine production differed between MIS-C and MAS. Immunomodulatory therapy given to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%). Clinical and laboratory improvement were observed in all cases, including 6 cases that did not require immunomodulatory therapy. No mortality was recorded in this cohort. CONCLUSION. MIS-C encompasses a broad phenotypic spectrum with clinical and laboratory features distinct from KD and MAS. FUNDING. This work was supported by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Allergy and Infectious Diseases; Rheumatology Research Foundation Investigator Awards and Medical Education Award; Boston Children’s Hospital Faculty Career Development Awards; the McCance Family Foundation; and the Samara Jan Turkel Center.

29 March 2018 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
DBDaniel F. Battafarano
Daniel F. Battafarano
MDMarcia Ditmyer
Marcia Ditmyer
MBMarcy B. Bolster
Marcy B. Bolster
John FitzGeraldJohn FitzGerald
John FitzGerald
CDChad Deal
Chad Deal
SMSeetha U. Monrad
Seetha U. Monrad

1 September 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JSJeffrey A. Sparks
Jeffrey A. Sparks
ZWZachary S Wallace
Zachary S Wallace
ASAndrea M Seet
Andrea M Seet
MGMilena A Gianfrancesco
Milena A Gianfrancesco
ZIZara Izadi
Zara Izadi
JYJinoos Yazdany
Jinoos Yazdany
Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. Results Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. Conclusions People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

12 July 2018 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
YZYongdong Zhao
Yongdong Zhao
EWEveline Y. Wu
Eveline Y. Wu
MOMelissa S. Oliver
Melissa S. Oliver
ACAshley M. Cooper
Ashley M. Cooper
MBMatthew L. Basiaga
Matthew L. Basiaga
PFPolly J. Ferguson
Polly J. Ferguson

1 June 2017 in Journal of Adolescent Health
Verified
Journal Article
Closed access
JHJonathan S. Hausmann
Jonathan S. Hausmann
CTCurrie Touloumtzis
Currie Touloumtzis
MWMatthew T. White
Matthew T. White
JCJames A. Colbert
James A. Colbert
HGHolly C. Gooding
Holly C. Gooding